Key Instruments

Providing confidence in your data

From qPCR and Western Blotting to automated liquid handlers and microplate readers, our instruments empower you to achieve the throughput, efficiency, accuracy and precision that your study deserves. Accelerate your discoveries with our workflows, and generate highly reliable data for your in vitro studies.

GET IN TOUCH NOW
Key Instruments

MODELS / SERVICES

ABI 7500                                                                                                              ABI Q6

 

Digital LightCycler®

 

Roche MagNA Pure LC 2.0 Automatic Nucleic Acid Isolation and Purification

Tanon 5200 Chemiluminescent Imaging System

ProteinSimple’s Jess™ Automated Western Blot System

Bio-Rad ChemiDoc XRS+

MP FastPrep-24™

Perkin Elmer Envision I & II

MSD MESO QuickPlex SQ 120

MSD MESO SECTOR S 600MM

TECAN M200pro & F200pro

sptlabtech dragonfly® discovery

Beckman Coulter Biomek i5 Automated Workstation

MultiMACS & autoMACS pro

gentleMACS™ Dissociator X3

BD FACSCanto™ II Clinical Flow Cytometry System

BD LSRFortessa™ Cell Analyzer

Beckman Coulter CytoFLEX LX Flow Cytometer

Committed to quality:

  • FDA part 11 compliant
  • Animal studies strictly follow AAALAC and ILAC guidelines
  • Electronically managed, traceable research data
  • Rigorous adherence to international GLP and QA best practices
  • Clients have real-time remote monitoring of studies

Want your scientific discoveries to become treatments? PharmaLegacy’s the right partner for you.

Contact Us

Providing Better Data For Critical Oncology Pipeline Decisions

To advance a compound from discovery to clinical, or to halt its development, is a huge and costly decision. For the benefit of you and your company, and for the well-being of patients in need of treatment, that decision needs to be based on correct information.

Download our Integrated In Vitro Oncology Assays brochure and see why over 300 pharmaceutical companies, including many global leaders, trust PharmaLegacy for the unbiased, accurate information they need to make critical oncology pipeline decisions.

    127

    We’re ready when you are.

    Tell us your pharmacology challenges.